DEMO, Win Medica and FARAN invest more than €400 million in Arcadia pharma hub

Tripoli emerges as a pharmaceutical production center

The industrial area of Tripoli in Arcadia is developing into a major pharmaceutical manufacturing center as investments by DEMO, ELPEN Group’s Win Medica and FARAN exceed €400 million. According to Capital.gr, the projects are at different stages of implementation and are associated with more than 1,500 direct and indirect jobs.

The facilities will expand Greece’s capacity to manufacture critical medicines, active pharmaceutical ingredients and technologically demanding drug-delivery products. At full development, some of the new lines could cover a significant share of European demand in selected therapeutic categories, giving the projects relevance beyond the domestic market.

DEMO targets active ingredients and injectable medicines

DEMO’s Tripoli project forms part of a €356 million investment plan and is expected to create more than 1,000 jobs. It will introduce industrial-scale capabilities that Greece has previously lacked, particularly in active pharmaceutical ingredients. Production will focus on penicillin medicines and chemically derived injectable oncology drugs.

Capital.gr reports that the planned capacity could correspond to about 34% of European demand for penicillin medicines and 35% of demand for chemically derived injectable oncology drugs. This would position the site within Europe’s effort to diversify pharmaceutical supply sources and bring more critical manufacturing back to the region.

Win Medica plans Greece’s largest solid-oncology plant

Win Medica is investing €80 million in Tripoli as part of ELPEN Group’s wider €350 million program. The company aims to establish Greece’s largest facility for solid-form oncology medicines, combining specialized production lines with research infrastructure, automation and new technologies.

The plant is designed as a smart factory using artificial intelligence and systems intended to reduce the environmental footprint of production. Its capacity is expected to cover more than 70% of Greece’s demand for oncology medicines while also supporting exports. The investment is linked to more than 300 jobs.

FARAN adds aseptic filling and delivery-device capacity

FARAN’s new facility will expand production and research in injectable medicines. It includes modern aseptic filling lines and infrastructure for assembling and packaging prefilled syringes and pharmaceutical pens, with scope for the future development of biotechnology medicines. The plant is being developed around international certification requirements and export markets.

The three projects are part of a broader €1.8 billion investment program presented by Greece’s pharmaceutical industry. Capital.gr says the national ecosystem includes more than 50 pharmaceutical companies, 45 factories and 27 research centers. Greek pharmaceutical products reach 147 countries, and exports have risen by 182% since the beginning of the country’s economic crisis. The concentration of new capacity in Tripoli is also creating demand for scientific and technical personnel, supported by a local vocational academy for pharmaceutical manufacturing.